Aradigm's Linhaliq Suffers 'No' For Reducing Time To Exacerbations At US FDA Panel
Executive Summary
Discordant results on Phase III primary endpoint in non-cystic fibrosis bronchiectasis patients troubled advisory committee members, although some suggested they would be more open to approval based upon secondary endpoint data on reduction in exacerbation frequency.
You may also be interested in...
Breathing Life Into Inhaled Antibiotics: US FDA Tries To Move Class Ahead After Two Rejections
Workshop on inhaled antibiotics serves as unusual post mortem after two public rejections at advisory committee level; agency clearly eager not to see development in field end.
Keeping Track: A Little Bit Of (Nearly) Everything
The latest drug development news and highlights from our US FDA Performance Tracker.
Corbus Takes On New Cystic Fibrosis Endpoint With Lenabasum
The US FDA has agreed to Corbus' plan to use pulmonary exacerbations as the only primary endpoint in a new large Phase II study, which is powered to serve as a registrational study.